EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Effects of blocking CD24 and CD47 ‘don't eat me’ signals in combination with rituximab in mantle‐cell lymphoma and chronic lymphocytic leukaemia

Andrea Aroldi iD, Mario Mauri iD, Daniele Ramazzotti, Matteo Villa iD, Federica Malighetti, Valentina Crippa, Federica Cocito, Chiara Borella, Elisa Bossi, Carolina Steidl, Chiara Scollo, Claudia Voena und 4 weitere

Journal of Cellular and Molecular Medicine · 2023-10 · 27 (20) · 3053-3064

DOI: 10.1111/jcmm.17868 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, online erschienen am 31.08.2023. Verfasst von Andrea Aroldi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Division, San Gerardo Hospital, Monza, Italy. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Associazione Italiana per la Ricerca sul Cancro.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mantle‐cell lymphoma (MCL) is a B‐cell non‐Hodgkin Lymphoma (NHL) with a poor prognosis, at high risk of relapse after conventional treatment. MCL‐associated tumour microenvironment (TME) is characterized by M2‐like tumour‐associated macrophages (TAMs), able to interact with cancer cells, providing tumour survival and resistance to immuno‐chemotherapy. Likewise, monocyte‐derived nurse‐like cells (NLCs) present M2‐like profile and provide proliferation signals to chronic lymphocytic leukaemia (CLL), a B‐cell malignancy sharing with MCL some biological and phenotypic features. Antibodies against TAMs targeted CD47, a ‘don't eat me’ signal (DEMs) able to quench phagocytosis by TAMs within TME, with clinical effectiveness when combined with Rituximab in pretreated NHL. Recently, CD24 was found as valid DEMs in solid cancer. Since CD24 is expressed during B‐cell differentiation, we investigated and identified consistent CD24 in MCL, CLL and primary human samples. Phagocytosis increased when M2‐like macrophages were co‐cultured with cancer cells, particularly in the case of paired DEMs blockade (i.e. anti‐CD24 + anti‐CD47) combined with Rituximab. Similarly, unstimulated CLL patients‐derived NLCs provided increased phagocytosis when DEMs blockade occurred. Since high levels of CD24 were associated with worse survival in both MCL and CLL, anti‐CD24‐induced phagocytosis could be considered for future clinical use, particularly in association with other agents such as Rituximab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Mantle-CellAdultHumansRituximabCD47 AntigenNeoplasm Recurrence, LocalPhagocytosisTumor MicroenvironmentCD24 Antigen

Stichwörter der Autor:innen

chronic lymphocytic leukemiadon't eat me signalimmunotherapymantle-cell lymphomanon hodgkin lymphoma

Substanzen

RituximabCD47 AntigenCD24 protein, humanCD24 AntigenCD47 protein, human

Autor:innen und Institutionen

  • Hematology Division, San Gerardo Hospital, Monza, Italy.
  • Department of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
  • Lymphoma Unit, Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Transfusion Medicine Unit, San Gerardo Hospital, Monza, Italy.
  • Department of Molecular Biotechnology and Health Sciences, University of Torino, Torino, Italy.
  • Department of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts, USA.

ORCID-Profile: Andrea Aroldi, Mario Mauri, Matteo Villa, Carlo Gambacorti-Passerini

Förderung

  • Associazione Italiana per la Ricerca sul Cancro

Zitieren

APA

Aroldi, A., Mauri, M., Ramazzotti, D., Villa, M., Malighetti, F., Crippa, V., Cocito, F., Borella, C., Bossi, E., Steidl, C., Scollo, C., Voena, C., Chiarle, R., Mologni, L., Piazza, R., & Gambacorti-Passerini, C. (2023). Effects of blocking CD24 and CD47 ‘don't eat me’ signals in combination with rituximab in mantle‐cell lymphoma and chronic lymphocytic leukaemia. Journal of Cellular and Molecular Medicine, 27(20), 3053-3064. https://doi.org/10.1111/jcmm.17868

Vancouver

Aroldi A, Mauri M, Ramazzotti D, Villa M, Malighetti F, Crippa V, et al. Effects of blocking CD24 and CD47 ‘don't eat me’ signals in combination with rituximab in mantle‐cell lymphoma and chronic lymphocytic leukaemia. Journal of Cellular and Molecular Medicine. 2023;27(20):3053-3064. doi:10.1111/jcmm.17868

BibTeX
@article{Aroldi2023,
  author = {Aroldi, Andrea and Mauri, Mario and Ramazzotti, Daniele and Villa, Matteo and Malighetti, Federica and Crippa, Valentina and Cocito, Federica and Borella, Chiara and Bossi, Elisa and Steidl, Carolina and Scollo, Chiara and Voena, Claudia and Chiarle, Roberto and Mologni, Luca and Piazza, Rocco and Gambacorti-Passerini, Carlo},
  title = {Effects of blocking CD24 and CD47 ‘don't eat me’ signals in combination with rituximab in mantle‐cell lymphoma and chronic lymphocytic leukaemia},
  journal = {Journal of Cellular and Molecular Medicine},
  year = {2023},
  volume = {27},
  number = {20},
  pages = {3053--3064},
  doi = {10.1111/jcmm.17868}
}
Kostenlos starten →